At the turn of the 20th century, bovine tuberculosis, a bacterial disease that infected cows and spilled over to humans via milk ran rampant in France. Today, a weakened form of that same ...

Monoclonal antibodies continue to show their ability to rid the brain of amyloid plaques. Trouble is, those antibodies need to be injected on the regular to keep taking down their targets in the brain ...

Epidemiological suggestions that the shingles vaccine might protect against dementia keep rolling in. Pascal Geldsetzer, Stanford University, presented his group’s latest findings at this year’s ...

Is it three steps forward one step back for blood tests? At the 18th Clinical Trials on Alzheimer’s Disease, held December 1–4 in San Diego, new data on the FDA-approved Fujirebio Lumipulse plasma ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...

What goes wrong first in the Alzheimer’s disease brain? Scientists led by Marc Aurel Busche of the U.K. Dementia Research Institute at University College London may have an answer. In the May 7 Neuron ...

Cerebrospinal fluid and plasma markers are now being used to help diagnose Alzheimer’s in memory clinics, but what about using them to stage the disease? That’s the next big step, said Henrik ...

The blood-brain barrier weakens during normal aging and in neurodegenerative disease, but the reasons are not fully understood. In the February 26 Nature, scientists led by Tony Wyss-Coray and Carolyn ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association ...

With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...